Jefferies & Co. analyst David Windley said the market for opioid addiction treatments is worth about $1 billion, and he believes Vivitrol would be a success if it is used in 10 percent to 20 percent of cases. That would be a major boost to its annual sales, which he said are currently about $25 million. Windley expects Alkermes to report $40 million in Vivitrol revenue in 2011.
I don't understand why he said only 41 million for 2011. Only if 10,000(out of 1.6 million patients) patients are enrolled total sales will be aroung 100 million.